Profilo
Victor Brantl currently works as a Vice President of Research and Development at Mepha AG.
Posizioni attive di Victor Brantl
Società | Posizione | Inizio |
---|---|---|
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | Direttore Tecnico/Scientifico/R&S | 08/02/2010 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | Health Technology |
- Borsa valori
- Insiders
- Victor Brantl